Biogen Announces Acquisition of Reata Pharmaceuticals
Total deal expected to be worth approximately $7.3 billion.
Biogen has officially announced a definitive agreement to acquire Reata Pharmaceuticals. As per financial terms, the purchase includes $172.50 per share in cash, equating to an overall value of approximately $7.3 billion. The deal comes amid the FDA’s approval of Skyclarys, Reata’s treatment for patients with Friedreich’s ataxia.
“With extensive expertise in rare disease product development and global commercialization, as demonstrated by Spinraza and the recent launch of Qalsody, we believe Biogen has the foundation in place to accelerate the delivery of Skyclarys to patients around the world,” said Christopher Viehbacher, President, CEO, Biogen. “This is a unique opportunity for Biogen to bolster our near-term growth trajectory, and Skyclarys is an excellent complement to our global portfolio of treatments for neuromuscular and rare disease.”
Reference: Biogen to Acquire Reata Pharmaceuticals. Biogen. July 28, 2023. Accessed July 31, 2023. https://investors.biogen.com/news-releases/news-release-details/biogen-acquire-reata-pharmaceuticals
Protecting Temperature-Sensitive Pharmaceuticals, Without Unnecessary Plastic Waste
March 24th 2025Advances in the life sciences are driving a significant increase in the number of temperature-sensitive pharmaceuticals. The packaging industry is meeting the moment with advances of its own, including high-performance, environmentally-friendly materials that allow life science companies meet stringent thermal requirements and ambitious CO2e reduction goals. In this episode, TemperPack’s CEO Peter Wells shares insights from working with life sciences to move to certified biobased, home compostable, and curbside recyclable shipping solutions.
